Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2026 07:30 ET | Source: Alveus Therapeutics Inc

Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases

Financing supports Phase 2 development of ALV-100, IND filing of ALV-200 and advancement of additional programs across the R&D pipeline ALV-100, a bifunctional GIPR antagonist / GLP-1R agonist,...
January 08, 2026 07:00 ET | Source: Rani Therapeutics, LLC

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
January 08, 2026 07:00 ET | Source: Antag Therapeutics

Antag Therapeutics demonstrates compelling potential of its novel GIPR antagonist for obesity, reporting excellent tolerability in Phase 1 and enhanced weight loss in amylin combination study

Combination of AT7687 and cagrilintide demonstrated enhanced weight loss effect in obese, insulin-resistant, pre-diabetic non-human primate (NHP) modelAdditional weight loss observed in combination...
January 07, 2026 13:01 ET | Source: King Faisal Prize

Pioneering Scientist Behind Revolutionary Weight-Loss Drugs and Leading Mathematician Honored with 2026 King Faisal Prize

Riyadh, Saudi Arabia, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Professor Svetlana Mojsov was announced this year's King Faisal Prize in Medicine laureate for her groundbreaking discoveries that are...
January 07, 2026 08:00 ET | Source: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals Announces Publication of IMPROVE-DiCE Phase 2a Data in Circulation, Demonstrating Ninerafaxstat as a Potential First-in-Class Therapy Targeting Cardiac Energetics in Cardiometabolic Disease

Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart failure with preserved ejection fraction (HFpEF) In...
January 06, 2026 01:56 ET | Source: MindRank AI Ltd.

MindRank Initiates Phase III "MOBILE" Trial for MDR-001: an Oral GLP-1RA Small Molecule Engineered with AI

MindRank Initiates Phase III "MOBILE" Trial for MDR-001: an Oral GLP-1RA Small Molecule Engineered with AI
January 05, 2026 08:05 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Appoints Doug Pagán as Chief Financial Officer

Kailera Therapeutics today announced the appointment of Doug Pagán as its Chief Financial Officer.
December 23, 2025 09:00 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Kailera Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference in January.
December 17, 2025 07:30 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Advances to Phase III of AI-Driven Drug Discovery Program Toward Validation of Multiple Potential Drug Compounds & Discoveries

NorthStrive Biosciences Advances to Phase III of AI-Driven Drug Discovery Program Toward Validation of Multiple Potential Drug Compounds & Discoveries
December 10, 2025 09:16 ET | Source: Research and Markets

US Dominates North America Digital Health for Obesity Market, Reaching USD 78.54 Billion by 2032

Dublin, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The "North America Digital Health For Obesity Market Size, Share & Industry Analysis Report By Component (Services, Software, and Hardware), By End-use...